Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 4
2005 2
2006 3
2008 4
2009 4
2010 4
2011 10
2012 12
2013 13
2014 9
2015 9
2016 23
2017 23
2018 24
2019 20
2020 13
2021 23
2022 22
2023 24
2024 5

Text availability

Article attribute

Article type

Publication date

Search Results

197 results

Results by year

Filters applied: . Clear all
Page 1
Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in Japanese patients with moderate to severe plaque, erythrodermic, or generalized pustular psoriasis: Efficacy and safety results from an open-label, phase 3 trial.
Imafuku S, Okubo Y, Tada Y, Ohtsuki M, Colston E, Napoli A, Shao Y, Banerjee S, Morita A. Imafuku S, et al. Among authors: ohtsuki m. J Dermatol. 2024 Mar;51(3):365-379. doi: 10.1111/1346-8138.17074. Epub 2024 Jan 24. J Dermatol. 2024. PMID: 38268101 Clinical Trial.
Exploring patient background and biomarkers associated with the development of dupilumab-associated conjunctivitis and blepharitis.
Kido-Nakahara M, Onozuka D, Izuhara K, Saeki H, Nunomura S, Takenaka M, Matsumoto M, Kataoka Y, Fujimoto R, Kaneko S, Morita E, Tanaka A, Saito R, Okano T, Miyagaki T, Aoki N, Nakajima K, Ichiyama S, Tonomura K, Nakagawa Y, Tamagawa-Mineoka R, Masuda K, Takeichi T, Akiyama M, Ishiuji Y, Katsuta M, Kinoshita Y, Tateishi C, Yamamoto A, Morita A, Matsuda-Hirose H, Hatano Y, Kawasaki H, Fukushima-Nomura A, Ohtsuki M, Kamiya K, Kabata Y, Abe R, Mitsui H, Kawamura T, Tsuji G, Furue M, Katoh N, Nakahara T. Kido-Nakahara M, et al. Among authors: ohtsuki m. Allergol Int. 2024 Apr;73(2):332-334. doi: 10.1016/j.alit.2023.12.001. Epub 2023 Dec 27. Allergol Int. 2024. PMID: 38151410 Free article. No abstract available.
The ability of biomarkers to assess the severity of atopic dermatitis.
Nakahara T, Onozuka D, Nunomura S, Saeki H, Takenaka M, Matsumoto M, Kataoka Y, Fujimoto R, Kaneko S, Morita E, Tanaka A, Saito R, Okano T, Miyagaki T, Aoki N, Nakajima K, Ichiyama S, Kido-Nakahara M, Tonomura K, Nakagawa Y, Tamagawa-Mineoka R, Masuda K, Takeichi T, Akiyama M, Ishiuji Y, Katsuta M, Kinoshita Y, Tateishi C, Yamamoto A, Morita A, Matsuda-Hirose H, Hatano Y, Kawasaki H, Fukushima-Nomura A, Ohtsuki M, Kamiya K, Kabata Y, Abe R, Mitsui H, Kawamura T, Tsuji G, Katoh N, Furue M, Izuhara K. Nakahara T, et al. Among authors: ohtsuki m. J Allergy Clin Immunol Glob. 2023 Sep 27;3(1):100175. doi: 10.1016/j.jacig.2023.100175. eCollection 2024 Feb. J Allergy Clin Immunol Glob. 2023. PMID: 37915726 Free PMC article.
Real-World Safety and Efficacy of Biosimilar CT-P13 in Patients with Immune-Mediated Inflammatory Diseases: Integrated Analysis of Three Japanese Prospective Observational Studies.
Takeuchi T, Nishikawa K, Yamada F, Morita A, Ohtsuki M, Suzuki Y, Watanabe M, Yamanaka H, Hibi T. Takeuchi T, et al. Among authors: ohtsuki m. Drug Saf. 2023 Oct;46(10):991-1005. doi: 10.1007/s40264-023-01340-1. Epub 2023 Sep 12. Drug Saf. 2023. PMID: 37700154 Free PMC article.
English version of Japanese guidance for biologics in treating atopic dermatitis.
Saeki H, Akiyama M, Abe M, Igarashi A, Imafuku S, Ohya Y, Katoh N, Kameda H, Kabashima K, Tsunemi Y, Hide M, Ohtsuki M; Committee for reviewing the safety of atopic dermatitis/urticaria treatment, Japanese Dermatological Association. Saeki H, et al. Among authors: ohtsuki m. J Dermatol. 2023 Oct;50(10):e311-e322. doi: 10.1111/1346-8138.16932. Epub 2023 Aug 31. J Dermatol. 2023. PMID: 37650357
Long-term safety and efficacy of risankizumab for the treatment of moderate-to-severe plaque psoriasis: Interim analysis of the LIMMitless open-label extension trial up to 5 years of follow-up.
Papp KA, Blauvelt A, Puig L, Ohtsuki M, Beissert S, Gooderham M, Amin AZ, Liu J, Wu T, Azam T, Stakias V, Espaillat R, Sinvhal R, Soliman AM, Pang Y, Chen MM, Lebwohl MG. Papp KA, et al. Among authors: ohtsuki m. J Am Acad Dermatol. 2023 Dec;89(6):1149-1158. doi: 10.1016/j.jaad.2023.07.1024. Epub 2023 Aug 6. J Am Acad Dermatol. 2023. PMID: 37553030 Free article. Clinical Trial.
TLR7/8 stress response drives histiocytosis in SLC29A3 disorders.
Shibata T, Sato R, Taoka M, Saitoh SI, Komine M, Yamaguchi K, Goyama S, Motoi Y, Kitaura J, Izawa K, Yamauchi Y, Tsukamoto Y, Ichinohe T, Fujita E, Hiranuma R, Fukui R, Furukawa Y, Kitamura T, Takai T, Tojo A, Ohtsuki M, Ohto U, Shimizu T, Ozawa M, Yoshida N, Isobe T, Latz E, Mukai K, Taguchi T, Hemmi H, Akira S, Miyake K. Shibata T, et al. Among authors: ohtsuki m. J Exp Med. 2023 Sep 4;220(9):e20230054. doi: 10.1084/jem.20230054. Epub 2023 Jul 18. J Exp Med. 2023. PMID: 37462944 Free PMC article.
197 results